Posts

AnesthesiaOS Wins Dell Healthcare and Life Sciences and Dell Center for …

/in , /by

AnesthesiaOS Wins Dell Healthcare and Life Sciences and Dell Center for …
Powered by Intel, the Tech Innovation Day Series provides a unique opportunity for startups to get their businesses in front of some of the most influential people in the industry. This year … The challenge showcased some of the best and brightest …
Read more on The Herald | HeraldOnline.com (press release)

The Aspen Institute and The Atlantic Announce 2014 Aspen Ideas Festival
The public dialogue will engage, over 10 days, a festival audience of more than 4,000 attendees between the Institute's campus at the Aspen Meadows and the town of Aspen, as well as those around the world following the festival online. One-on-one …
Read more on DigitalJournal.com

Can you help? “I need an automated hook up between DPD and Sage for parcel …
Obviously, manually entering addresses must prove to be a massive chunk of time in the working day and we're all in favour of clever automation ideas. Have you got any tips for this seller? … I completely understand that every business is different …
Read more on TameBay

5i Sciences Hires the General Manager of its Acute Care Product Group and Announces Favorable Clinical Results

/in , /by


San Diego, CA (PRWEB) February 21, 2014

5i Sciences, a medical technology company focused on airway management products, announces the appointment of Jan Barker as General Manager of its Acute Care Product group.

“This is a key appointment for our Company”, said Dr. Richard Rose, CEO of 5i Sciences. “Jan is a senior executive with broad experience in healthcare and managing operational growth. We have worked closely with Jan in her role as an Advisor to our Company. We are delighted that success in the development of our Acute Care Product line has created a role for someone of her stature and skill set.”

Ms. Barker has held a number of executive positions in healthcare related companies. She was formerly Vice President of Stanford Children’s Hospital, regional CEO of MedPartners, Inc., COO of Alere Medical and Partner at MedVenture Associates, a venture capital firm. Ms. Barker holds a Masters Degree in Health Science from UC Davis and Stanford University.

“Managing upper airway collapse is a major concern in the fields of sleep medicine and anesthesia care”, said Ms. Barker. “5i Sciences’ proprietary cNEP technology has unique promise as a simple to use and better tolerated option for effective airway management. I’m honored to play a role in the company’s growth as it brings its innovative products to these important medical markets.”

The Company also announced the presentation of results from a completed study in the acute care setting at the international conference of the Society of Anesthesia and Sleep Medicine. In this study of 54 adults receiving sedation for routine colonoscopy, the application of 5i Science’s Airway Management System was safe and produced statistically significant reductions in sedation related breathing problems and improved oxygenation.

About 5i Sciences:

5i Sciences is developing its proprietary continuous negative external pressure (cNEP) technology for important medical and consumer applications. The Company is dedicated to offering simple to use, safe and well-tolerated products that keep the upper airway open. For more information, visit http://www.5iSciences.com.







Life Sciences Veteran Michael Davies Ph.D. Joins TraceLink to Lead Global Sales Growth

/in , /by


Wakefield, MA (PRWEB) January 23, 2014

TraceLink Inc., the leader in global pharmaceutical serialization, drug track and trace compliance and supply network performance solutions, announced today that life sciences industry veteran Michael Davies Ph.D. has joined the company as the Senior Vice President of Global Sales and Business Development.

Mike joins the TraceLink leadership team and will be responsible for shaping the company’s worldwide sales strategy and driving overall revenue generation. In addition, he is charged with building new business and channel partnerships to expand global market access for TraceLink’s cloud-based software application platform providing solutions for companies across the global life sciences supply chain.

“We are excited to have Mike join TraceLink and lead our global expansion in the life sciences supply chain,” said Shabbir Dahod, President and CEO of TraceLink. “His sales leadership, global experience and deep knowledge of the unique needs of the pharmaceutical industry further enhance the strong team we have built creating solutions that help the industry meet global regulatory compliance requirements and improve performance across the supply chain from ingredient to patient.”

“A major factor in my decision to join TraceLink is the company’s passion for tackling some of the biggest challenges facing the global pharmaceutical industry today: protecting patient safety, ensuring global track and trace compliance and improving access to global markets for needed medicines,” said Mike Davies, Senior Vice President of Global Sales and Business Development at TraceLink. “I am thrilled to have the opportunity to join a team so dedicated to this mission and I look forward to helping TraceLink grow its global business and build long-term customer relationships.”

With an eighteen year career in the biopharmaceutical industry, Mike has a proven track record of building and scaling sales organizations, developing markets and helping customers succeed at companies such as Oracle, Phase Forward and Parke-Davis (now Pfizer). As Vice President for Global Sales in the Health Sciences Global Business Unit at Oracle Corporation, he helped shape business unit strategy and led sales execution for Oracle’s Life Sciences and Healthcare solutions. At Phase Forward, Mike was instrumental in helping the company rapidly grow revenues by leading sales teams and designing and implementing channel partner programs for the company’s electronic data management and pharmacovigilance solutions. Mike started his career in various Life Sciences roles at Parke-Davis and Pfizer and he holds a Bachelor of Science degree from the University of Sunderland and a Ph.D. in Physiology & Pharmacology from the University of Bradford.

TraceLink serves the global life science industry through the TraceLink Life Sciences Cloud network platform, pharmaceutical track and trace solutions and supply network performance applications that help pharmaceutical companies and supply network partners connect, share key business data and collaborate across supply, production and distribution operations. Market leaders, including four of the top-10 pharmaceutical companies, use a single integrated connection to the TraceLink Life Sciences Cloud for:

    Compliance with pharmaceutical serialization, product tracing and government reporting regulations for the US H.R. 3204 Drug Quality and Security Act, China, Brazil, Korea and other global drug track and trace regulations
    Creation of a supply chain control tower that improves speed across external supply activities, increases visibility and control across the outsourced production lifecycle and enhances agility in meeting patient demand across global markets

To learn more about TraceLink’s scalable solutions serving pharmaceutical companies, CMO/CPOs, wholesale distributors and pharmacies of all sizes, complexities and locations across the globe, visit us at http://www.tracelink.com.

About TraceLink

TraceLink protects patients, enables health, grows profits and ensures compliance for companies across the global Life Sciences network through the TraceLink Life Sciences Cloud. The TraceLink Life Sciences Cloud is an Amazon AWS-based cloud application platform which enables complete global connectivity, visibility and traceability of pharmaceuticals from raw materials to patient. A single point and click connection to the Life Sciences Cloud delivers the information, insight and collaboration needed to improve performance and reduce risk across global supply, manufacturing and distribution operations. Winner of numerous industry awards including the Amazon AWS Global Start-Up Challenge Grand Prize and the Edison Award for Innovation in Health Management, the TraceLink Life Sciences Cloud is relied upon by businesses across the globe to meet strategic goals in ensuring global compliance, fighting drug counterfeiting, improving on-time and in-full delivery, protecting product quality and reducing operational cost. For more information on TraceLink and our solutions, visit http://www.tracelink.com or follow us on LinkedIn.

TraceLink is funded by FirstMark Capital. FirstMark Capital is an early stage venture capital firm based in New York City. Our mission is to partner with exceptional entrepreneurs who are changing the world by solving meaningful problems. We have built a deeply engaged community among the extraordinary teams in our network to spread ideas and opportunities. We are privileged to work alongside the founders of remarkable businesses like Pinterest, Lumosity, Aereo, TapAd, Shopify, Riot Games, and dozens more. Visit us in New York City or online at firstmarkcap.com and @FirstMarkCap.







weMultiply and LSAN Announce Strategic Partnership in Support of the Life Sciences Angel Networks Third Annual MedTech Conference

/in , /by

(PRWEB) June 18, 2013

weMultiply, a New York-based angel investment and business acceleration group, has partnered with the Life Sciences Angel Network (LSAN) to support LSAN’s Third Annual MedTech Conference, and provide ongoing strategic and operational backing. Through its relationship with LSAN, weMultiply provides its engaged ventures with access to the region’s most diverse, active group of life science and Health IT angel investors and investment groups.

Launched in 2010 by Dr. Milena Adamian, LSAN funds, mentors, and provides operational support to funded companies within the life sciences and Health IT sectors. The Conference, “Build or Flip: Why and When? A Unique Look at the Medical Devices and Healthcare Services Sectors,” focused on key issues facing investors and entrepreneurs today – whether to build early-stage ventures for the ‘long haul’ or a quick sale; how to best attract and successfully engage with exit partners; and, trends and developments within the rapidly-changing markets for healthcare device and service technologies. Panelists included founders of successful Health IT and life sciences ventures, as well as industry heavyweights from organizations including Johnson & Johnson, McKinsey, Bain Capital, Bank of America, Becton Dickinson, Telcare and more.

“Partnering with LSAN offers an opportunity to be a part of the most dynamic industry conversations, as well as direct access to a wide network of active investors,” said weMultiply Managing Director Lena Feygin. “Milena’s team, as expected, has created an engaging program featuring some of the top names in the industry.”

“The markets for Health IT and life sciences technologies have seen remarkable growth in the past few years, and as these segments scale we are focused on driving the industry forward and sourcing the highest-quality opportunities,” said LSAN founder Dr. Milena Adamian. “Strategic partnerships with groups like weMultiply directly enhance our ability to target the ventures most likely to succeed in the current market climate.”

“By leveraging its network of active sales channels, weMultiply identifies and invests in ventures with a high probability of rapidly securing institutional clients,” said weMultiply Managing Director Jesse Williamson. “This approach both accelerates the implementation of innovative health technologies, and mitigates a key risk associated with early stage healthcare investments. LSAN has developed a uniquely efficient program to engage, identify and place targeted investments, and we are excited to support it.”

Backed by the 9.8 Group of Companies, weMultiply seeks out, validates, and invests in emerging health & wellness technology ventures which can benefit from its network of active institutional sales channels. The weMultiply S.A.L.E.® program provides early stage and startup companies with direct investment, access to capital through the company’s angel and venture capital networks, as well as the strategic tools, leadership, advice and health industry regulatory and compliance expertise required to ensure the proper roll-out and successful growth of each venture.

Companies accepted into the S.A.L.E.® program are provided with an aggressive development and launch program designed to prepare them for market competition and success on the global stage.

For more information on weMultiply and the S.A.L.E. program, please visit http://www.weMultiply.com.

For more information on LSAN, visit http://www.lsanfund.com.

About weMultiply:

A subsidiary of the 9.8 Group, WeMultiply empowers game-changing Health & Wellness technology innovations with the capital and strategic resources to lead in tomorrow’s market. Our program invests directly in each accelerated venture, and pairs each investment with marketing and development resources from the 9.8 Group of health care advertising agencies, its mentor network, and subsidiary businesses. Learn more at wemultiply.com.

About LSAN:

Founded in 2010 by Dr. Milena Adamian in New York, LSAN was built with the understanding that to help our portfolio companies succeed, we needed to provide them with funding as well as operational support and an access to a broad network of healthcare investors, key opinion leaders, corporate players and other entrepreneurs.







TraceLink Wins 2013 Red Herring 100 Global Award for Life Sciences Cloud

/in , /by


Wakefield, MA (PRWEB) November 22, 2013

TraceLink Inc., the leader in global pharmaceutical serialization, drug traceability and supply network performance solutions, announced today that it has been named winner of Red Herring’s 2013 Top 100 Global Award, recognizing the year’s most audacious and far reaching private technology companies and entrepreneurs from across the globe. TraceLink’s Life Sciences Cloud global application platform and global customer community of pharmaceutical industry innovators were key foundations for the award.

“Protecting patients from counterfeit drugs, improving access to safe, quality medicines and ensuring compliance with regulations like the Drug Quality and Security Act is our core mission,” said Shabbir Dahod, President and CEO of TraceLink. “We are honored that Red Herring recognized our efforts in building an innovative cloud application platform that helps Life Science executives think differently about their global supply chain networks, business processes and IT architectures to meet growing supply and demand challenges.”

The TraceLink Life Sciences Cloud global network platform, pharmaceutical track and trace solutions and supply network performance applications help pharmaceutical companies and their diverse supply network partners connect, share key business data and collaborate across supply, production and distribution operations. Market leaders, including four of the top-10 pharmaceutical companies, use the TraceLink Life Sciences Cloud to:

    Comply with pharmaceutical serialization, product tracing and government reporting requirements for the US H.R. 3204 Drug Quality and Security Act, China, Brazil, Korea and other global drug track and trace regulations
    Build a supply chain control tower that improves speed across external supply activities, reduces risk across the production lifecycle and increases agility in meeting patient demand across diverse global markets
    Create a flexible global IT infrastructure that simplifies integration across thousands of supply relationships, improves control over billions of transactions and enables management of terabytes of transaction data through a single connection to the Life Sciences Cloud

Red Herring’s Top 100 Global list has become a mark of distinction for identifying promising new companies and entrepreneurs. Red Herring editors were among the first to recognize that companies such as Facebook, Twitter, Google, Yahoo, Skype, Salesforce.com, YouTube, and eBay would change the way we live and work.

“Choosing the companies with the strongest potential was by no means a small feat,” said Alex Vieux, publisher and CEO of Red Herring. “After rigorous contemplation and discussion, we narrowed our list down from hundreds of candidates from across the globe to the Top 100 Winners. We believe TraceLink embodies the vision, drive and innovation that define a successful entrepreneurial venture. TraceLink should be proud of its accomplishment, as the competition was the strongest it has ever been.”

The TraceLink Life Sciences Cloud platform is designed for and built upon Amazon AWS Cloud. This highly scalable and reliable design enables TraceLink to serve pharmaceutical companies, CMO/CPOs, wholesale distributors and pharmacies of all sizes, complexities and locations across the globe. Learn more at http://www.tracelink.com.

About TraceLink

TraceLink protects patients, enables health, grows profits and ensures compliance for companies across the global Life Sciences network through the TraceLink Life Sciences Cloud. The TraceLink Life Sciences Cloud is an Amazon AWS-based cloud application platform which enables complete global connectivity, visibility and traceability of pharmaceuticals from raw materials to patient. A single point and click connection to the Life Sciences Cloud delivers the information, insight and collaboration needed to improve performance and reduce risk across global supply, manufacturing and distribution operations. Winner of numerous industry awards including the Amazon AWS Global Start-Up Challenge Grand Prize and the Edison Award for Innovation in Health Management, the TraceLink Life Sciences Cloud is relied upon by businesses across the globe to meet strategic goals in ensuring global compliance, fighting drug counterfeiting, improving on-time and in-full delivery, protecting product quality and reducing operational cost. For more information on TraceLink and our solutions, visit http://www.tracelink.com or follow us on LinkedIn.

TraceLink is funded by FirstMark Capital. FirstMark Capital is an early stage venture capital firm based in New York City. Our mission is to partner with exceptional entrepreneurs who are changing the world by solving meaningful problems. We have built a deeply engaged community among the extraordinary teams in our network to spread ideas and opportunities. We are privileged to work alongside the founders of remarkable businesses like Pinterest, Lumosity, Aereo, TapAd, Shopify, Riot Games, and dozens more. Visit us in New York City or online at firstmarkcap.com and @FirstMarkCap.







Disaster Medical Sciences: Towards Defining A New Discipline

/in , /by

Disaster Medical Sciences: Towards Defining A New Discipline
To develop metrics for disaster management, it is useful to identify the essential elements necessary to continue to provide service (e.g., taking care of patients) and use these for continuity of business operations planning. If one or more of these …
Read more on Health Affairs (blog)

AllDigital Expands Nationally on Latisys Platform
IRVINE, CA — (Marketwired) — 01/13/14 — Latisys, a leading national provider of hybrid cloud hosting and data center solutions, today announced an IT Infrastructure as a Service (IaaS) agreement with AllDigital Inc., a leading provider of digital …
Read more on SYS-CON Media (press release)